BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol

20260 citationsJournal Articlehybrid Open Access

Authors

Soemeya F. Haj Mohammad · Leiden University Medical Center

Ilse A.C. Spiekman · Erasmus MC Cancer Institute

Karlijn Verkerk · Oncode Institute

Florentine A.J. Verbeek · Oncode Institute

Hans Timmer · Leiden University Medical Center

Maud A. van Maren · Erasmus MC Cancer Institute

Laurien J. Zeverijn

Abstract

Dabrafenib plus trametinib is highly effective in patients with recurrent or progressive BRAF<sup>V600E</sup>-mutated CNS-tumors, representing a valuable therapeutic option for these vulnerable patients.

Topics & Keywords

Melanoma and MAPK Pathways Brain Metastases and Treatment Neurofibromatosis and Schwannoma Cases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Cancer

Volume 238, pp. 116674-116674

DOI: 10.1016/j.ejca.2026.116674

Field-Weighted Citation Impact: 0.00